Please assess the completion status of the following clinical trial:

Trial Title: Safety, Efficacy and PK of BIVV001 in Pediatric Patients With Hemophilia A

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria :~* Participant must be younger than 12 years of age, at the time of signing the informed consent.~* Severe hemophilia A defined as \<1 international units per deciliter (IU/dL) (\<1 percent \[%\]) endogenous Factor VIII (FVIII) as documented either by central laboratory testing at Screening or in historical medical records from a clinical laboratory demonstrating \<1% FVIII coagulant activity (FVIII:C) or a documented genotype known to produce severe hemophilia A.~* Previous treatment for hemophilia A (prophylaxis or on-demand) with any recombinant and/or plasma-derived FVIII, or cryoprecipitate for at least 150 exposure days (EDs) for participants aged 6 to \<12 years and above 50 EDs for participants aged \<6 years.~* Weight above or equal to 10 kg.~Exclusion criteria:~* History of hypersensitivity or anaphylaxis associated with any FVIII product.~* History of a positive inhibitor (to FVIII) test defined as greater than or equal to (\>=) 0.6 Bethesda units (BU/mL), or any value greater than or equal to the lower sensitivity cut-off for laboratories with cut-offs for inhibitor detection between 0.7 and 1.0 BU/mL, or clinical signs or symptoms of decreased response to FVIII administrations. Family history of inhibitors would not exclude the participant.~* Positive inhibitor test result, defined as \>=0.6 BU/mL at Screening.~The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- Gender: MALE
- Minimum Age: None
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- BIVV001: Participants aged <6 Years (Type: EXPERIMENTAL): Participants aged less than (\<) 6 years received BIVV001 at a dose of 50 international units per kilogram (IU/kg) intravenous (IV) injection once-weekly (QW) prophylaxis for 52 weeks.
- BIVV001: Participants aged 6 to <12 Years (Type: EXPERIMENTAL): Participants aged 6 to \<12 years received BIVV001 at a dose of 50 IU/kg IV injection QW prophylaxis for 52 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).